PET-Technology
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 10.7m | 14.5m | 16.7m | 30.9m | 21.8m | 24.5m | 27.8m |
| % growth | 184 % | 36 % | 15 % | 85 % | (30 %) | 13 % | 13 % |
| Profit | (2.1m) | (1.7m) | (1.0m) | 3.0m | <1m | 6.7m | 5.1m |
| % profit margin | (20 %) | (12 %) | (6 %) | 10 % | 4 % | 27 % | 18 % |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Early VC | ||
$50.0m | Acquisition | ||
| Total Funding | - | ||
Recent News about PET-Technology
EditPet-net.ru operates a federal network of Nuclear Medicine centers specializing in advanced cancer diagnostics and non-invasive treatments. The company offers PET CT scans, which combine positron emission tomography (PET) and computed tomography (CT) to provide high-precision cancer diagnosis. Additionally, Pet-net.ru provides CyberKnife treatments, a non-invasive and painless alternative to surgery for various tumors. The business serves patients across multiple cities in Russia, including Moscow, Ufa, Ekaterinburg, Lipetsk, Kursk, Orel, Tambov, and Belgorod. Pet-net.ru's business model revolves around offering high-tech medical services that require specialized equipment and expertise, thereby generating revenue through patient consultations, diagnostic procedures, and treatment sessions. The company prides itself on its modern equipment, a unique team of specialists, and a patient-centric approach, having conducted over 130,000 PET CT examinations to date.
Keywords: cancer diagnostics, PET CT, CyberKnife, non-invasive treatment, Nuclear Medicine, high-precision, Russia, tumors, medical services, patient-centric.